Precision BioSciences Inc (DTIL)
7.70
-0.38
(-4.70%)
USD |
NASDAQ |
Nov 14, 16:00
7.70
0.00 (0.00%)
After-Hours: 20:00
Precision BioSciences Cash from Operations (Quarterly): -5.912M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -5.912M |
| June 30, 2024 | -14.87M |
| March 31, 2024 | -18.98M |
| December 31, 2023 | -8.423M |
| September 30, 2023 | -23.09M |
| June 30, 2023 | -21.13M |
| March 31, 2023 | -31.46M |
| December 31, 2022 | -21.84M |
| September 30, 2022 | 29.19M |
| June 30, 2022 | -24.22M |
| March 31, 2022 | -28.87M |
| December 31, 2021 | -23.68M |
| September 30, 2021 | -23.90M |
| June 30, 2021 | -31.34M |
| Date | Value |
|---|---|
| March 31, 2021 | 68.07M |
| December 31, 2020 | -13.45M |
| September 30, 2020 | -22.22M |
| June 30, 2020 | -25.80M |
| March 31, 2020 | -25.91M |
| December 31, 2019 | -20.56M |
| September 30, 2019 | -13.98M |
| June 30, 2019 | -16.58M |
| March 31, 2019 | -19.91M |
| December 31, 2018 | -12.91M |
| September 30, 2018 | -15.05M |
| June 30, 2018 | -9.31M |
| March 31, 2018 | -14.45M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-31.46M
Minimum
Mar 2023
68.07M
Maximum
Mar 2021
-14.42M
Average
-22.03M
Median
Cash from Operations (Quarterly) Benchmarks
| Assembly Biosciences Inc | -17.10M |
| TG Therapeutics Inc | -12.20M |
| Protagonist Therapeutics Inc | -27.86M |
| Alector Inc | -50.73M |
| Entrada Therapeutics Inc | -24.27M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.064M |
| Cash from Financing (Quarterly) | 3.733M |
| Free Cash Flow | -48.36M |
| Free Cash Flow Per Share (Quarterly) | -0.8201 |
| Free Cash Flow to Equity (Quarterly) | -5.76M |
| Free Cash Flow Yield | -107.5% |